Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Kalantari, Shiva ^a   Rutishauser, Dorothea ^b,c   Samavat, Shiva ^d   Nafar, Mohsen ^d,e   Mahmudieh, Leyla ^d   Rezaei Tavirani, Mostafa ^f   Zubarev, Roman A ^b,c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SCIENCE FOR LIFE LABORATORY   (Sweden)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMIN; ALPHA 1 MICROGLOBULIN; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CERULOPLASMIN; COMPLEMENT COMPONENT C3; HEMOPEXIN; LEUCIN RICH ALPHA 2 GLYCOPROTEIN; MEMBRANE PROTEIN; PROTEOME; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; URINALYSIS; URINE LEVEL; ADOLESCENT; GLOMERULONEPHRITIS, IGA; KIDNEY; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROTEIN DEGRADATION; PROTEOMICS; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEOLYSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84891946966     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080830     Document Type: Article

References (58)

1. Barratt J, Feehally J (2005) IgA nephropathy. J Am Soc Nephrol 16:2088-2097. doi:10.1681/ASN.2005020134. PubMed: 15930092. (Pubitemid 41716440)
2. D'Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179-196. doi: 10.1016/j.semnephrol.2004.01.001. PubMed: 15156525. (Pubitemid 38685989)
3. Hsu SI, Ramirez SB, Winn MP, Bonventre JV, Owen WF (2000) Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 57:1818-1835. PubMed: 10792601. (Pubitemid 30252274)
4. Rauta V, Finne P, Fagerudd J, Rosenlöf K, Törnroth T et al. (2002) Factors associated with progression of IgA nephropathy are related to renal function-A model for estimating risk of progression in mild disease. Clin Nephrol 58:85-94. doi:10.5414/CNP58085. PubMed: 12227693. (Pubitemid 34855087)
5. Haas M (1997) Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 29:829-842. doi: 10.1016/S0272-6386 (97) 90456-X. PubMed: 9186068. (Pubitemid 27251835)
6. Lee HS, Lee MS, Lee SM, Lee SY, Lee ES et al. (2005) Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant 20:342-348. doi:10.1093/ndt/gfh633. PubMed: 15618239. (Pubitemid 40276890)
7. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS et al. (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534-545. doi:10.1038/ki.2009. 243. PubMed: 19571791.
8. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A et al. (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76:546-556. doi:10.1038/ki. 2009.168. PubMed: 19571790.
9. Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ et al. (2011) Pathologic Predictors of Renal Outcome and Therapeutic Efficacy in IgA Nephropathy: Validation of the Oxford Classification. Clin J Am Soc Nephrol 6:2175-2184. doi:10.2215/CJN.11521210. PubMed: 21852672.
10. Lee H, Yi SH, Seo MS, Hyun JN, Jeon JS et al. (2012) Validation of the Oxford Classification of Iga Nephropathy: A Single-Center Study in Korean Adults. Korean J Intern Med 27:293-300. doi:10.3904/kjim. 2012.27.3.293. PubMed: 23019394.
11. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N et al. (2011) Validation of the oxford classification of IgA nephropathy. Kidney Int 80:310-317. doi:10.1038/ki.2011.126. PubMed: 21544062.
12. Alamartine E, Sauron C, Laurent B, Sury A, Seffert A et al. (2011) The Use of the oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 6:2384-2388. doi:10.2215/CJN.01170211. PubMed: 21885791.
13. Troyanov S, Fervenza FC (2011) Validating the oxford classification of IgA nephropathy. Clin J Am Soc Nephrol 6:2335-2336. doi:10.2215/CJN.08440811. PubMed: 21979911.
14. Kistler AD, Serra AL, Siwy J, Poster D, Krauer F et al. (2013) Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant. PLOS ONE 8:e53016. doi:10.1371/journal.pone.0053016. PubMed: 23326375.
15. Nagaraj N, Mann M (2011) Quantitative analysis of the intra- and interindividual variability of the normal urinary proteome. J Proteome Res 10:637-645. doi:10.1021/pr100835s. PubMed: 21126025.
16. Rappsilber J, Ishihama Y, Mann M (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 75:663-670. doi:10.1021/ac026117i. PubMed: 12585499. (Pubitemid 36176744)
17. Lindén M, Lind SB, Mayrhofer C, Segersten U, Wester K et al. (2012) Proteomics analysis of urinary biomarker candidates for nunmuscle invasive bladder cancer. Proteomics 12:135-144. doi:10.1002/pmic.201000810. PubMed: 22065568.
18. Geladi P, Esbensen K (1991) Regression on multivariate images principal component regression for modeling, prediction and visual diagnostic-tools. J Chemometr 5:97-111. doi:10.1002/cem. 1180050206.
19. Wold S, Jonsson J, Sjostrom M, Sandberg M, Rannar S (1993) DNA and peptide sequences and chemical processes multivariately modeled by principal component analysis and partial least-Squares projections to latent structures. Anal Chim Acta 277:239-253. doi: 10.1016/0003-2670 (93) 80437-P. (Pubitemid 23158002)
20. Stella C, Beckwith-Hall B, Cloarec O, Holmes E, Lindon JC et al. (2006) Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res 5:2780-2788. doi:10.1021/pr060265y. PubMed: 17022649. (Pubitemid 44604232)
21. Sampson DL, Parker TJ, Upton Z, Hurst CP (2011) A comparison of methods for classifying clinical samples based on proteomics data: A case study for statistical and machine learning approaches. PLOS ONE 6:e24973. doi:10.1371/journal.pone.0024973. PubMed: 21969867.
22. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W et al. (2003) DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 4:3. doi:10.1186/gb-2003-4-5-p3.
23. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4:R70. doi:10.1186/gb-2003-4-10-r70. PubMed: 14519205.
24. Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarevand Ra et al. (2011) Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics 10:M110:002980. PubMed: 21191032.
25. Raana G, Khurhsid R, Rasheed A, Aftab ML (2009) Clinical significance and prognostic value of low molecular weight 'tubular' protein, apha-1-acid glycoprotein in diabetes, Pak. J Physiol 5:34-36.
26. Bazzi C (2003) Composition of proteinuria in primary glomerulonephritides: association with tubolo-interstitial damage, outcome and response to therapy. G Ital Nefrol 20:346-355. PubMed: 14523895.
27. Geladi P, Kowalski B (1986) Partial leastsquares regression: A tutorial. Anal Chim Acta 185:1-17. doi:10.1016/0003-2670 (86) 80028-9.
28. Li SM, Yan JX, Yang L (2006) Effect of astragalus injection on renal tubular function in patients with IgA nephropathy. Zhonqquo Zhonq Xi Yi; He Za Jie Zhi 26:504-507
29. Woo KT, Lau YK, Lee GSL, Wong KS, Wei SS et al. (1997) Pattern of proteinuria in IgA nephropathy. Nephrol 3:31-34. doi:10.1111/j. 1440-1797.1997.tb00185.x. (Pubitemid 27161077)
30. Woo KT, Tan YO, Yap HK, Lau YK, Tay JS et al. (1981) Beta-2-microglobulin in mesengial IgA nephropathy. Nephron 37:78-81.
31. Allhorn M, Berggård T, Nordberg J, Olsson ML, Akerström B (2002) Processing of lipocalin alpha (1)-microglobulin by hemoglobin induces heme-binding and heme-degradation properties. Blood 99:1894-1901. doi:10.1182/blood. V99.6.1894. PubMed: 11877257. (Pubitemid 34525466)
32. Lundberg S, Gunnarsson I, Jacobson SH (2012) Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol 46:148-155. doi:10.3109/00365599.2011.644635. PubMed: 22214235.
33. Wang JJ, Yao XD, Zhang YY (1998) Detection of serum and urinary lipoprotein a in patients with renal disease. Nephrol 4:27-30. doi: 10.1046/j.1440-1797.1998.d01-2.x.
34. Rao PV, Lu X, Standley M, Pattee P, Neelima G et al. (2007) Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 30:629-637. doi:10.2337/dc06-2056. PubMed: 17327332. (Pubitemid 46354345)
35. Julian BA, Wittke S, Novak J, Good DM, Coon JJ et al. (2007) Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 28:4469-4483. doi: 10.1002/elps.200700237. PubMed: 18004714. (Pubitemid 350259049)
36. Luczak M, Formanowicz D, Pawliczak E, Wanic-Kossowska M, Wykretowicz A et al. (2011) Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. Proteome Sci 9:25. doi:10.1186/1477-5956-9-25. PubMed: 21569504.
37. Boes E, Fliser D, Ritz E, König P, Lhotta K et al. (2006) Apolipoprotein A IV-predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 17:528-536. doi: 10.1681/ASN.2005070733. PubMed: 16382017.
38. Kronenberg F (2009) Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 5:677-689. doi:10.1038/nrneph.2009.173. PubMed: 19935815.
39. Lingenhel A, Lhotta K, Neyer U, Heid IM, Rantner B (2006) Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria. J Lipid Res 47:2071-2079. doi:10.1194/jlr. M600178-JLR200. PubMed: 16788210. (Pubitemid 44401996)
40. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N et al. (2006) Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724-1734. doi:10.1681/ASN.2005090923. PubMed: 16687629. (Pubitemid 43794676)
41. Onda K, Ohsawa I, Ohi H, Tamano M, Mano S et al. (2011) Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol 12:64. doi: 10.1186/1471-2369-12-64. PubMed: 22111871.
42. Vivekanandan-Giri A, Slocum JL, Buller CL, Basrur V, Ju W, et al. (2011) Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics 2011:214715
43. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P et al. (2007) Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 13:7370-7379. doi: 10.1158/1078-0432. CCR-07-0747. PubMed: 18094419.
44. Suzuki M, Ross GF, Wiers K, Nelson S, Bennett M et al. (2007) Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol 22:2047-2057. doi:10.1007/s00467-007-0608-x. PubMed: 17901988. (Pubitemid 350090711)
45. Negi VS, Aggarwal A, Dayal R, Naik S, Misra R (2000) Complement degradation product C3d in urine: marker of lupus nephritis. J Rheumatol 27:380-383. PubMed: 10685801. (Pubitemid 30095468)
46. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR et al. (2007) Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 18:913-922. doi:10.1681/ASN.2006070767. PubMed: 17301191. (Pubitemid 46434508)
47. Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW et al. (2005) Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 16:169-174. PubMed: 15563570. (Pubitemid 43073169)
48. Nasr SH, Fidler ME, Cornell LD, Leung N, Cosio FG et al. (2012) Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant 0:1-9. PubMed: 22872726.
49. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA et al. (2012) C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 82:465-473. doi:10.1038/ki.2012.212. PubMed: 22673887.
50. Qiaoling Z, Xiaoyun J, Wei W, Shuhong D, Yaqin P et al. (2009) Altered P-selectin and CD44 expression in the renal tissues and peripheral blood of children with IgA nephropathy. Int Urol Nephrol 41:703-711. doi:10.1007/s11255- 008-9512-y. PubMed: 19125345.
51. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA et al. (2009) Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 284:30825-30835. doi:10.1074/jbc. M109.047605. PubMed: 19726691.
52. Ohashi N, Urushihara M, Kobori H (2009) Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy. Minerva Urol Nefrol 61:55-66. PubMed: 19417726.
53. Melenhorst WB, van den Heuvel MC, Timmer A, Huitema S, Bulthuis M et al. (2006) ADAM19 expression in human nephrogenesis and renal disease: Associations with clinical and structural deterioration. Kidney Int 70:1269-1278. doi:10.1038/sj.ki.5001753. PubMed: 16900093. (Pubitemid 44435178)
54. Webb DJ, Gonias SL (1998) A modified human alpha 2-macroglobulin derivative that binds tumor necrosis factor-alpha and interleukin-1 beta with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice. Lab Invest 78:939-948. PubMed: 9714181. (Pubitemid 28378208)
55. Ambrus G, Gál P, Kojima M, Szilágyi K, Balczer J et al. (2003) Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J Immunol 170:1374-1382. PubMed: 12538697. (Pubitemid 36139504)
56. Wei P, Zhao YG, Zhuang L, Ruben S, Sang QX (2001) Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. Biochem Biophys Res Commun 280:744-755. doi:10.1006/bbrc.2000.4200. PubMed: 11162584. (Pubitemid 32924493)
57. Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30. doi:10.1093/nar/28.7.e27. PubMed: 10592173. (Pubitemid 30047706)
58. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34:D354-D357. doi:1 093/nar/gkj102. PubMed: 16381885.